Saw an article about another NASH failure and in t
Post# of 147673
(Total Views: 622)
Posted On: 12/13/2021 8:37:14 AM
Re: nmbr1stckpckr #112308
Saw an article about another NASH failure and in that article was this:
“In mid-2020, France’s Genfit reported that its drug elafibranor failed a Phase III trial in NASH. The year before, Gilead Sciences’ selonsertib flunked a Phase III trial. Gilead’s firsocostat and cilofexor were also unsuccessful in NASH. Boehringer Ingelheim and Pharmaxis’ BI 1467335 also failed in trials.
For quite some time, the leading company in the NASH race was Intercept Pharmaceuticals and its drug obeticholic acid (OCA). In June 2020, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) rejecting their application. The CRL stated that it could not be approved because of uncertainty about the efficacy of the treatment. There were also concerns over the risk-benefit profile for the drug.
NGM Bio took a hard hit at today’s news, with shares dropping 48.73% in premarket trading.“
Here’s the article link:
https://www.pharmalive.com/ngms-aldafermin-la...h-failure/
“In mid-2020, France’s Genfit reported that its drug elafibranor failed a Phase III trial in NASH. The year before, Gilead Sciences’ selonsertib flunked a Phase III trial. Gilead’s firsocostat and cilofexor were also unsuccessful in NASH. Boehringer Ingelheim and Pharmaxis’ BI 1467335 also failed in trials.
For quite some time, the leading company in the NASH race was Intercept Pharmaceuticals and its drug obeticholic acid (OCA). In June 2020, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) rejecting their application. The CRL stated that it could not be approved because of uncertainty about the efficacy of the treatment. There were also concerns over the risk-benefit profile for the drug.
NGM Bio took a hard hit at today’s news, with shares dropping 48.73% in premarket trading.“
Here’s the article link:
https://www.pharmalive.com/ngms-aldafermin-la...h-failure/
(10)
(0)